■ "From diagnosis to prognosis confirmation and treatment, we will establish an AI-based total genome diagnosis platform with Theragen Bio's own technology."

Theragen Bio (CEO: Samuel Hwang), a global genome service provider and AI-based biopharmaceutical company, announced on the 7th that it has completed patent acquisition for "DeepOmics Marker™", an AI-based patient classification molecular subtype calculation device.

The official name of the patent is 'DeepOmics Marker™', MOLECULAR SUBTYPE CLASSIFICATION APPARATUS, METHOD FOR CALCULATING MOLECULAR SUBTYPES IN A DISEASE AND COMPUTER PROGRAM'. The goal is to effectively classify patients using deep learning-based programs and derive major markers for each disease subtype to find targets for developing customized drugs or new drugs for each patient. The company has so far obtained two patents for DeepOmics Marker™ and three patents for DeepOmics Neo™. In the future, the company plans to develop customized treatment targets and new drugs for each patient through patent applications for genomic big data service "DeepOmics™" and detailed services.

Unlike the existing analysis method, 'DeepOmics MarkerT™' is a groundbreaking method that analyzes the difference in expression ranking between genes compared to normal in each sample, enabling more accurate classification of diseases than existing methods. In addition, since molecular subtypes are automatically discovered in the disease cohort, it is possible to discover molecular subtypes of diseases that have been difficult to classify molecular subtypes by conventional methods. In particular, as a result of large-scale breast cancer cohort analysis, patients with poor prognosis among Luminal A molecular subtype patients classified as low-risk groups by existing molecular subtype classification methods could be distinguished by DeepOmics Marker™, which verified their excellent performance.

DeepOmics™, a genomic big data service, is an AI-based diagnostic prognosis analysis platform developed by Theragen Bio. It consists of "DeepOmics Neo™",a platform for research and development of anticancer vaccines, "DeepOmics Marker™", a platform for analyzing symptoms and prognosis before companion diagnosis for individual patients, "DeepOmics Network™, a platform to analyze drug responses from patietns and "DeepOmics Target™", a platform to select effective treatment drug targets.

"If we apply DeepOmicsMarker™ to each patient and classify them into detailed molecular subtypes, we expect to predict the responsiveness of individual existing drugs, especially by discovering treatment targets for malignant molecular subtypes without current treatment," said Hwang Tae-soon, CEO of Theragen Bio.

Meanwhile, Theragen Bio is developing a personalized anti-cancer vaccine based on the principle of removing cancer cells by administering customized antigens predicted through cancer genomic analysis in the form of messenger ribonucleic acid (mRNA), peptide (amino acid conjugate), and dendritic cells. Theragen Bio is a leading genomic analysis company in Korea, and has been expanding its business to develop personalized cancer vaccines, target treatments for rectal cancer, BI platform development, and AI medical big data since physical division at Theragen Etex in May 2020.

▶ Introduction of Theragen Bio

Theragen Bio provides genome service to more than 700 domestic medical and research institutes over 40 countries abroad, being as a global genome service provider and AI-based biopharmaceutical company specializing in the development of the fourth-generation personalized anti-cancer drugs. Theragenbio strives to realize precision medicine based on genomic technology, thereby providing the true hope and practical solutions for welfare and health of mankind.